Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

Michael Nork // Publications // Aug 01 2005

PubMed ID: 16007519

Author(s): Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis. 2005 Aug 1;41(3):e27-8. Epub 2005 Jun 28. PMID 16007519

Journal: Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America, Volume 41, Issue 3, Aug 2005

Candida endophthalmitis represents the most serious ocular complication of candidemia. The pharmacokinetics and pharmacodynamics of fluconazole, amphotericin B, and flucytosine are fairly well established in endophthalmitis therapy. There remains a paucity of clinical data regarding the utility of new antimycotic agents in the treatment of fungal chorioretinitis and endophthalmitis. We report a case of clinical failure of caspofungin in the management of Candida albicans endophthalmitis associated with poor vitreous penetration.